Tenolig140 mg+200 mg+30 mg+500 mg+12.5 mg

Tenolig is a combination nutraceutical/dietary supplement combining a structural protein (type I collagen), a glycosaminoglycan (chondroitin sulfate), a viscoelastic polysaccharide (sodium hyaluronate), an amino acid (L-arginine), and an antioxidant vitamin/collagen-synthesis cofactor (vitamin C). It is used for the following indications:

Common/Widely Marketed Uses

• Nutritional support for joint health, including as an adjunct in mild-to-moderate osteoarthritis and general age-related joint discomfort, alongside standard medical care.
• Support for skin and connective-tissue health, providing raw materials (collagen, vitamin C as a cofactor for collagen synthesis) relevant to skin elasticity and wound/tissue repair.
• General nutritional supplementation of cartilage-matrix components (collagen, chondroitin sulfate, hyaluronate) for individuals with increased demand, such as active individuals or older adults.

Notes on Evidence

The evidence for meaningful symptomatic benefit from this specific multi-ingredient combination is limited and largely preliminary; individual components (e.g., chondroitin sulfate) have more studied but still modest and inconsistent evidence for osteoarthritis symptom relief. Tenolig is a supportive/adjunct nutritional supplement, not a substitute for prescribed treatment of significant or advanced joint disease, and it is not FDA-approved as a drug for any indication.

Each dose of Collagen Type-I + Chondroitin Sulfate + Sodium Hyaluronate + L-Arginine + Vitamin C typically provides a combination of:

• Type I Collagen (often as hydrolyzed collagen peptides) — a structural protein that is a major component of skin, tendon, bone matrix, and cartilage.
• Chondroitin Sulfate — a glycosaminoglycan naturally found in cartilage, typically sourced from bovine, porcine, or marine/shark cartilage.
• Sodium Hyaluronate — the sodium salt of hyaluronic acid, a key component of synovial fluid and skin extracellular matrix.
• L-Arginine — a semi-essential amino acid and precursor of nitric oxide.
• Vitamin C (ascorbic acid) — an antioxidant vitamin and essential cofactor for endogenous collagen synthesis.

Exact strengths of each component vary by brand and dosage form (capsule, sachet/powder for oral solution, or tablet); refer to the specific product label for exact quantities.

Tenolig is an oral combination dietary supplement formulated to support joint, skin, and connective-tissue health. It combines type I collagen and chondroitin sulfate — both structural components of cartilage and connective tissue — with sodium hyaluronate, a lubricating and hydrating component of synovial fluid and skin, L-arginine, an amino acid involved in vascular and tissue-repair physiology, and vitamin C, which is required by the body's own enzymes (prolyl and lysyl hydroxylase) to synthesize and cross-link new collagen.

Tenolig is marketed in Bangladesh and elsewhere as an over-the-counter nutritional supplement, typically available as capsules, sachets (oral powder/solution), or tablets, and is generally used as a nutritional adjunct rather than as a primary treatment for diagnosed joint disease.

Tenolig belongs to the class of nutraceutical/dietary supplements for joint and connective-tissue health, combining a structural protein, a glycosaminoglycan, a polysaccharide, an amino acid, and a vitamin cofactor.

Mechanism of Action

Collagen Type-I + Chondroitin Sulfate + Sodium Hyaluronate + L-Arginine + Vitamin C is proposed to act through several complementary mechanisms. Type I collagen peptides supply amino acid building blocks (including glycine, proline, and hydroxyproline) that may stimulate chondrocyte and fibroblast matrix synthesis. Chondroitin sulfate is a glycosaminoglycan component of cartilage that may help maintain cartilage matrix integrity and has been reported in some studies to modestly inhibit degradative enzymes involved in cartilage breakdown. Sodium hyaluronate contributes to the viscoelasticity and lubricating properties of synovial fluid and skin extracellular matrix, and may support tissue hydration. L-arginine is a nitric oxide precursor with roles in vasodilation, blood flow, and wound/tissue repair, and is also a substrate for growth-hormone-related pathways. Vitamin C is an essential cofactor for prolyl and lysyl hydroxylase, the enzymes required for stable collagen triple-helix formation, and also acts as an antioxidant limiting oxidative damage to joint and connective tissue.

Pharmacokinetics

Orally ingested collagen peptides are digested into smaller peptides and free amino acids, some of which are absorbed intact and distributed to connective tissues. Chondroitin sulfate undergoes partial degradation in the gut, with a fraction of intact and depolymerized chondroitin absorbed and detectable in plasma and, to a lesser extent, in joint tissue. Sodium hyaluronate taken orally is largely degraded by intestinal bacteria and enzymes, with limited direct systemic absorption of intact high-molecular-weight hyaluronate. L-arginine is absorbed from the small intestine, undergoes first-pass hepatic and intestinal metabolism, and is a substrate for nitric oxide synthase. Vitamin C is absorbed via active intestinal transport, widely distributed in tissues, and excreted renally, with excess intake excreted largely unchanged in urine.

Tenolig capsules or tablets should be swallowed whole with a glass of water; sachets/oral powder formulations should be dissolved or mixed as directed on the label and consumed immediately. It is generally taken with meals to improve tolerability. Follow the specific product's instructions, as formulations and strengths vary by brand.

Tenolig has the following clinically relevant interaction considerations, related mainly to its chondroitin sulfate and L-arginine components:

• Anticoagulants and antiplatelet agents (e.g., warfarin, heparin, aspirin, clopidogrel): Chondroitin sulfate has been reported, in isolated cases, to potentiate the effect of warfarin, and L-arginine has a mild antiplatelet/vasodilatory effect at higher doses; concurrent use may theoretically increase bleeding risk. If combined with warfarin, INR should be monitored more closely, especially when starting or stopping Tenolig.
• Antihypertensive medications and PDE5 inhibitors (e.g., sildenafil): L-arginine's nitric-oxide-precursor, vasodilatory mechanism could theoretically add to the blood-pressure-lowering effect of these medications; monitor blood pressure if combined.
• Nitrates: Theoretical additive vasodilatory/hypotensive effect with L-arginine; use with caution.
• Diabetes medications: L-arginine may have a mild effect on insulin secretion/glucose handling in some individuals; monitor blood glucose if combined with antidiabetic therapy.

Side effects of Tenolig are generally mild:

• Common: Mild gastrointestinal effects such as nausea, bloating, flatulence, abdominal discomfort, or diarrhea (more often associated with the vitamin C or L-arginine components at higher intake).
• Less common: Headache or flushing (related to L-arginine's vasodilatory effect), mild heartburn.
• Rare: Hypersensitivity/allergic reactions (rash, itching, swelling), particularly in individuals with animal-source or shellfish-related allergies (see Contraindications).

Safety data specific to Tenolig in pregnancy and lactation are limited. As a general precaution, it should be used during pregnancy and breastfeeding only if clearly needed and after consulting a physician, who can weigh the potential benefit against any potential risk; it should not be assumed to be safe based on its status as a nutritional supplement alone.

• Bleeding risk: Use with caution in patients on anticoagulant or antiplatelet therapy, or with a bleeding disorder or planned surgery, due to potential additive effects of chondroitin sulfate and L-arginine (see Interactions); discontinuation before elective surgery may be advised by the treating physician.
• Herpes simplex virus history: L-arginine has been theoretically associated with triggering or worsening herpes simplex outbreaks in some individuals based on limited data; discuss with a clinician before use if there is a relevant history.
• Low blood pressure or use with antihypertensive/PDE5-inhibitor medications: L-arginine's vasodilatory, nitric-oxide-precursor mechanism could theoretically add to blood-pressure-lowering effects; use with caution and monitor blood pressure (see Interactions).
• Limited evidence base: Evidence for symptomatic benefit from this specific multi-ingredient combination is limited and preliminary; it should be presented and used with evidence-appropriate expectations.
• Not a substitute for prescribed treatment: Tenolig does not replace physician-prescribed treatment for significant, advanced, or inflammatory joint disease; a physician should be consulted for persistent, worsening, or severe joint symptoms.
• Allergy/sourcing: Individuals with shellfish or other animal-source allergies should verify the specific product's chondroitin sulfate/collagen source before use (see Contraindications).

There is no well-documented severe toxicity syndrome specific to overdose of Tenolig as a nutritional supplement. Excessive intake, particularly of the L-arginine or vitamin C components, may cause gastrointestinal upset (nausea, diarrhea, abdominal cramping) or, theoretically, additive blood-pressure-lowering effects from L-arginine. In case of a large accidental overdose or if concerning symptoms occur, seek immediate medical attention or contact emergency services/a poison control center; do not attempt specific home treatment beyond stopping the product and seeking medical advice.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal Impairment

No well-established dose adjustment exists for Tenolig in renal impairment; use with caution and medical guidance, considering the amino acid (L-arginine) load.

Hepatic Impairment

No specific dose adjustment is established for hepatic impairment; use per general precautions and physician guidance.

Elderly

Tenolig is commonly used in older adults for joint and connective-tissue nutritional support; consider concurrent medications (particularly anticoagulants/antihypertensives) and overall health status (see Interactions and Precautions).

Pediatric Patients

Not routinely recommended in children and adolescents; see Pediatric Uses.

Duration of use of Tenolig is typically a trial period of about 4 to 12 weeks to assess perceived benefit for joint or connective-tissue symptoms, with longer-term use possible under medical or product-label guidance if benefit is perceived; periodic reassessment of continued need is advisable.

Collagen Type-I + Chondroitin Sulfate + Sodium Hyaluronate + L-Arginine + Vitamin C is classified as a nutraceutical/dietary supplement combination for joint and connective-tissue health (structural protein + glycosaminoglycan + polysaccharide + amino acid + vitamin).

Collagen Type-I + Chondroitin Sulfate + Sodium Hyaluronate + L-Arginine + Vitamin C combines type I collagen and chondroitin sulfate (structural cartilage/connective-tissue components), sodium hyaluronate (a lubricating, hydrating component of synovial fluid and skin), L-arginine (a nitric oxide precursor supporting blood flow and tissue repair), and vitamin C (an essential cofactor for endogenous collagen synthesis and an antioxidant), together intended to support joint, skin, and connective-tissue health.

Safety and efficacy of Tenolig have not been established in children and adolescents, and it is not routinely recommended for pediatric use. Joint and connective-tissue nutritional needs in children should generally be met through a balanced diet, and any supplement use in a child should only be undertaken on a physician's specific advice.